CanaryBio Passes Global Phase 3 Clinical Trial DSMB Review

Canaria Bio (CEO Nahanik) announced on the 31st that the global Phase 3 clinical trial of Oregobomab, conducted at 162 sites across 16 countries targeting new ovarian cancer patients, has passed the review by the DSMB (Data Safety Monitoring Board).

This global Phase 3 clinical trial undergoes clinical data review every six months by the DSMB, and in this review, the recommendation was to continue the trial. The next DSMB review is scheduled for September, six months from now.

The global Phase 3 trial is conducted with two cohorts: adjuvant chemotherapy and neoadjuvant chemotherapy. Recruitment for the neoadjuvant chemotherapy cohort, which enrolls 230 patients, has already been completed. The adjuvant chemotherapy cohort plans to recruit 370 patients and currently has enrolled 321 patients.

In the Phase 2 clinical trial conducted on 97 patients in the United States and Italy, the progression-free survival (PFS) of patients treated with Oregobomab was 42 months, which is 30 months longer than the existing standard treatment.

CEO Nahanik said, "Considering that global blockbuster immuno-oncology drugs generating annual sales in the trillions of won extend PFS by about 3 to 5 months, this is an encouraging result."